Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Receivables - Other: 2009-2018

Historic Receivables - Other for Cytokinetics (CYTK) over the last 10 years, with Dec 2018 value amounting to $4.6 million.

  • Cytokinetics' Receivables - Other fell 94.46% to $575,000 in Q2 2019 from the same period last year, while for Jun 2019 it was $575,000, marking a year-over-year decrease of 94.46%. This contributed to the annual value of $4.6 million for FY2018, which is 53.09% down from last year.
  • Cytokinetics' Receivables - Other amounted to $4.6 million in FY2018, which was down 53.09% from $9.7 million recorded in FY2017.
  • Cytokinetics' Receivables - Other's 5-year high stood at $46.6 million during FY2014, with a 5-year trough of $12,000 in FY2015.
  • Its 3-year average for Receivables - Other is $4.8 million, with a median of $4.6 million in 2018.
  • In the last 5 years, Cytokinetics' Receivables - Other soared by 932,820.00% in 2014 and then crashed by 99.97% in 2015.
  • Yearly analysis of 5 years shows Cytokinetics' Receivables - Other stood at $46.6 million in 2014, then tumbled by 99.97% to $12,000 in 2015, then soared by 100.00% to $24,000 in 2016, then skyrocketed by 40,350.00% to $9.7 million in 2017, then plummeted by 53.09% to $4.6 million in 2018.